Is BCAB or PPBT more profitable?

BioAtla's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Purple Biotech N/A -136.79% -100.38%

Does the media refer more to BCAB or PPBT?

In the previous week, Purple Biotech had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for BioAtla. Purple Biotech's average media sentiment score of 1.50 beat BioAtla's score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAtla 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend PPBT or BRTX?

Purple Biotech presently has a consensus price target of $30.00, indicating a potential upside of 1,900.00%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PPBT or BRTX?

In the previous week, Purple Biotech had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Biorestorative Therapies. Purple Biotech's average media sentiment score of 1.50 beat Biorestorative Therapies' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biorestorative Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ERNA or PPBT more profitable?

Purple Biotech's return on equity of -136.79% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Purple Biotech N/A -136.79% -100.38%

Does the media favor ERNA or PPBT?

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 2 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 1.50 beat Ernexa Therapeutics' score of -1.67 indicating that Purple Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Negative Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate CDIO or PPBT?

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,900.00%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor CDIO or PPBT?

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 2 articles in the media. Purple Biotech's average media sentiment score of 1.50 beat Cardio Diagnostics' score of -0.65 indicating that Purple Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate APVO or PPBT?

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,900.00%. Given Purple Biotech's higher probable upside, analysts plainly believe Purple Biotech is more favorable than Aptevo Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, APVO or PPBT?

Purple Biotech is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A Purple Biotech N/A N/A -$26.39M -$23.25 N/A

Is APVO or PPBT more profitable?

Purple Biotech's return on equity of -136.79% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Purple Biotech N/A -136.79% -100.38%

Does the media prefer APVO or PPBT?

In the previous week, Purple Biotech had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Aptevo Therapeutics. Purple Biotech's average media sentiment score of 1.50 beat Aptevo Therapeutics' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Purple Biotech (PPBT) Competitors

$1.50 +0.07 (+4.90%)

As of 04:00 PM Eastern

Compare

PPBT vs. BCAB, BRTX, ERNA, CDIO, and APVO

Should you buy Purple Biotech stock or one of its competitors? Purple Biotech's main competitors and comparable companies include BioAtla (BCAB), Biorestorative Therapies (BRTX), Ernexa Therapeutics (ERNA), Cardio Diagnostics (CDIO), and Aptevo Therapeutics (APVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Purple Biotech compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

BioAtla's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Purple Biotech	N/A	-136.79%	-100.38%

BioAtla has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Purple Biotech had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for BioAtla. Purple Biotech's average media sentiment score of 1.50 beat BioAtla's score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAtla	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Purple Biotech has lower revenue, but higher earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	2.88	-$59.61M	-$41.72	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

BioAtla currently has a consensus price target of $200.00, indicating a potential upside of 5,663.69%. Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,900.00%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Purple Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.2% of BioAtla shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BioAtla beats Purple Biotech on 6 of the 11 factors compared between the two stocks.

How does Purple Biotech compare to Biorestorative Therapies?

Purple Biotech (NASDAQ:PPBT) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Purple Biotech has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Biorestorative Therapies has higher revenue and earnings than Purple Biotech. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
Biorestorative Therapies	$360K	14.23	-$14.24M	-$1.07	N/A

In the previous week, Purple Biotech had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Biorestorative Therapies. Purple Biotech's average media sentiment score of 1.50 beat Biorestorative Therapies' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Purple Biotech has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Purple Biotech's return on equity of -136.79% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-136.79%	-100.38%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Purple Biotech presently has a consensus price target of $30.00, indicating a potential upside of 1,900.00%. Given Purple Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Purple Biotech is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Purple Biotech beats Biorestorative Therapies on 8 of the 14 factors compared between the two stocks.

How does Purple Biotech compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Ernexa Therapeutics has higher revenue and earnings than Purple Biotech. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	9.14	-$14.08M	-$14.35	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

Ernexa Therapeutics has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Ernexa Therapeutics had 1 more articles in the media than Purple Biotech. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 2 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 1.50 beat Ernexa Therapeutics' score of -1.67 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Negative
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ernexa Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 562.25%. Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 1,900.00%. Given Purple Biotech's higher probable upside, analysts plainly believe Purple Biotech is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Purple Biotech's return on equity of -136.79% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Purple Biotech	N/A	-136.79%	-100.38%

Summary

Ernexa Therapeutics beats Purple Biotech on 6 of the 11 factors compared between the two stocks.

How does Purple Biotech compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 2 articles in the media. Purple Biotech's average media sentiment score of 1.50 beat Cardio Diagnostics' score of -0.65 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cardio Diagnostics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Purple Biotech has a consensus target price of $30.00, suggesting a potential upside of 1,900.00%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cardio Diagnostics has higher revenue and earnings than Purple Biotech. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	506.16	-$6.50M	-$2.92	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

Purple Biotech has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -80.78% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-80.78%	-74.33%
Purple Biotech	N/A	-136.79%	-100.38%

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 3.0% of Purple Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cardio Diagnostics beats Purple Biotech on 7 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 0.5% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Purple Biotech had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Purple Biotech and 1 mentions for Aptevo Therapeutics. Purple Biotech's average media sentiment score of 1.50 beat Aptevo Therapeutics' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptevo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Purple Biotech has a consensus target price of $30.00, indicating a potential upside of 1,900.00%. Given Purple Biotech's higher probable upside, analysts plainly believe Purple Biotech is more favorable than Aptevo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aptevo Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Purple Biotech is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

Purple Biotech's return on equity of -136.79% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Purple Biotech	N/A	-136.79%	-100.38%

Summary

Purple Biotech beats Aptevo Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.33M	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.13	269.75	24.74
Price / Sales	N/A	1,274.20	652.34	108.60
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.14	17.66	11.27	6.42
Net Income	-$26.39M	-$13.25M	$3.45B	$347.12M
7 Day Performance	2.04%	5.36%	3.56%	2.48%
1 Month Performance	-3.54%	-1.74%	-0.58%	-1.04%
1 Year Performance	-92.96%	61.36%	77.52%	23.22%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	3.4289 of 5 stars	$1.50 +4.9%	$30.00 +1,900.0%	-93.3%	$1.33M	N/A	N/A	20	Positive News Gap Up High Trading Volume
BCAB BioAtla	1.6781 of 5 stars	$3.35 +2.8%	$200.00 +5,870.1%	-80.4%	$5.56M	$2M	N/A	60	Gap Up
BRTX Biorestorative Therapies	0.9897 of 5 stars	$0.21 +6.1%	N/A	-85.9%	$5.35M	$360K	N/A	7	News Coverage Upcoming Earnings
ERNA Ernexa Therapeutics	2.9633 of 5 stars	$4.42 +28.1%	$30.00 +578.7%	-90.1%	$5.15M	N/A	N/A	10	News Coverage Earnings Report Upcoming Earnings Analyst Downgrade
CDIO Cardio Diagnostics	0.9134 of 5 stars	$1.74 +6.1%	N/A	-48.1%	$5.15M	$16.57K	N/A	1	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. BCAB, BRTX, ERNA, CDIO, and APVO

How does Purple Biotech compare to BioAtla?

Summary

How does Purple Biotech compare to Biorestorative Therapies?

Summary

How does Purple Biotech compare to Ernexa Therapeutics?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Summary

How does Purple Biotech compare to Aptevo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. BCAB, BRTX, ERNA, CDIO, and APVO

How does Purple Biotech compare to BioAtla?

Is BCAB or PPBT more profitable?

Which has more volatility and risk, BCAB or PPBT?

Does the media refer more to BCAB or PPBT?

Which has higher earnings and valuation, BCAB or PPBT?

Do analysts prefer BCAB or PPBT?

Do institutionals and insiders believe in BCAB or PPBT?

Summary

How does Purple Biotech compare to Biorestorative Therapies?

Do institutionals and insiders believe in PPBT or BRTX?

Which has more volatility & risk, PPBT or BRTX?

Which has preferable valuation & earnings, PPBT or BRTX?

Does the media prefer PPBT or BRTX?

Is PPBT or BRTX more profitable?

Do analysts recommend PPBT or BRTX?

Summary

How does Purple Biotech compare to Ernexa Therapeutics?

Which has higher valuation and earnings, ERNA or PPBT?

Which has more volatility & risk, ERNA or PPBT?

Does the media favor ERNA or PPBT?

Do analysts prefer ERNA or PPBT?

Do institutionals & insiders hold more shares of ERNA or PPBT?

Is ERNA or PPBT more profitable?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Does the media favor CDIO or PPBT?

Which has more risk and volatility, CDIO or PPBT?

Do analysts rate CDIO or PPBT?

Which has preferable earnings & valuation, CDIO or PPBT?

Is CDIO or PPBT more profitable?

Do institutionals and insiders hold more shares of CDIO or PPBT?

Summary

How does Purple Biotech compare to Aptevo Therapeutics?

Do insiders & institutionals believe in APVO or PPBT?

Does the media prefer APVO or PPBT?

Do analysts rate APVO or PPBT?

Which has more volatility & risk, APVO or PPBT?

Which has preferable valuation and earnings, APVO or PPBT?

Is APVO or PPBT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools